[Skin cancer after organ transplantation].
Hackethal
M
M
Klinik für Dermatologie, Venerologie und Allergologie, Charité, Humboldt-Universität Berlin.
Ulrich
C
C
Stockfleth
E
E
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004008:Diclofenac / Q000008:administration & dosage / Q000627:therapeutic use; D005782:Gels; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D000077271:Imiquimod; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016377:Organ Transplantation / Q000009:adverse effects*; D010778:Photochemotherapy; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy / Q000209:etiology*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D005782:Gels; D007166:Immunosuppressive Agents; D004008:Diclofenac; D006820:Hyaluronic Acid; D000077271:Imiquimod